Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: BTAI

BioXcel Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for BTAI. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

BioXcel Therapeutics, Inc. (NASDAQ: BTAI) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 06:02 UTC.

What BioXcel Therapeutics, Inc. does

BioXcel Therapeutics is a biopharmaceutical company that uses artificial intelligence and machine learning to develop medicines in neuroscience and immuno-oncology, primarily by identifying new therapeutic uses for existing approved drugs or clinically evaluated candidates. The company's lead neuroscience asset, BXCL501 (marketed as IGALMI), was approved by the FDA for acute treatment of agitation associated with schizophrenia or bipolar disorder in adults and is being evaluated for additional indications including agitation associated with Alzheimer's dementia.

Summarized from BioXcel Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

BTAI no longer appears among SEC's registered filers -- it may have been acquired, merged, or delisted. The figures on this page reflect the company's final filings and are no longer refreshed.

Key facts

Valuation
Return on equity73.22%

Revenue, margins & earnings

FY2022: net loss $166M on revenue $375,000$375,000FY2022FY2023: net loss $179M on revenue $1M$1MFY2023FY2024: net loss $60M on revenue $2M$2MFY2024FY2025: net loss $70M on revenue $642,000$642,000FY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-08-14
  • 2026-08-14DirectorStock Option (Right to Buy)Award17,000—
  • 2026-06-17Chief Scientific OfficerOption exercise35—
  • 2026-06-17CEO and PresidentOption exercise219—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does BioXcel Therapeutics, Inc. do?

BioXcel Therapeutics is a biopharmaceutical company that uses artificial intelligence and machine learning to develop medicines in neuroscience and immuno-oncology, primarily by identifying new therapeutic uses for existing approved drugs or clinically evaluated candidates.

When did BTAI last file with the SEC?

BioXcel Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-06. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 06:02 UTC. This page is also available as JSON at /api/data?ticker=BTAI and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for BTAI and 5,000+ tickers.

Create a free account — keep BTAI
For your agent
GET /api/data?ticker=BTAI

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt